Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVe-CLL/SLL: Rituximab, Idelalisib, and Venetoclax in R/R CLL/SLL
NCT03639324Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of idelalisib and venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (6 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Recommended Phase 2 Dose at 41 Months. Planned start Oct 2020; status: withdrawn.
02
Drugs
idelalisibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03639324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639324.